TY - JOUR
T1 - Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
AU - Schwartz, D. H.
AU - Clements, M. L.
AU - Gorse, G.
AU - Belshe, R.
AU - Izu, A.
AU - Duliege, A. M.
AU - Berman, P.
AU - Twaddell, T.
AU - Stablein, D.
AU - Sposto, R.
AU - Siliciano, R.
AU - Matthews, T.
N1 - Funding Information:
We thank Dr A Ammann, Dr Pat East, Dr Wayne Koff, Dr Mary Clare Walker, Dr Dani Bolagnesi, and members of the AIDS Vaccine Evaluation Group for support and insight, the clinical and laboratory staff at Johns Hopkins University, St Louis Univerity, Duke University, and Genentech Inc, and Ms Carol Smith, and Ms Donna Brown, and other members of EMMES Corp for providing data management. We also thank the volunteers whose participation makes possible the development of experimental HIV vaccines. Supported by NIAID contracts N01-AI- 05061 and NOl-AI-05064.
PY - 1993/7/10
Y1 - 1993/7/10
N2 - A recombinant human immunodeficiency virus 1 IIIB (HIV-1IIIB) gp120 subunit vaccine (IIIB-rgp120/HIV-1, Genentech) was tested for safety and immunogenicity in a randomised, double-blind, placebo-controlled phase-I trial. HIV-1- seronegative adult volunteers received three 100 μg or 300 μg doses of IIIB-rgp120/HIV-1 in alum adjuvant (10 vaccinees in each group), or alum adjuvant alone (8 vaccinees), at 0, 4, and 32 weeks by intramuscular injection. The three injections were well tolerated in both vaccine groups. Antibodies that neutralised homologous HIV-1IIIB were induced in 9 of 10 recipients after three 300 μg doses, and 6 of these 9 sera also neutralised heterologous HIV-1SF2. A dose response was evident, since three 100 μg injections induced lower titres of HIV-1IIIB neutralising antibodies and in fewer recipients (5 of 9) than the higher dose, with no neutralisation of HIV-1SF2. Similarly, syncytia-inhibiting, CD4-rgp120- blocking, and HIV-1IIIB V3-binding antibodies were induced in a dose dependent manner. Response to the 300 μg per dose vaccination occurred in a larger proportion of volunteers and at higher mean titres than seen in previous human trials with other recombinant envelope subunit vaccines or live vaccinia-env priming followed by envelope subunit boosting.
AB - A recombinant human immunodeficiency virus 1 IIIB (HIV-1IIIB) gp120 subunit vaccine (IIIB-rgp120/HIV-1, Genentech) was tested for safety and immunogenicity in a randomised, double-blind, placebo-controlled phase-I trial. HIV-1- seronegative adult volunteers received three 100 μg or 300 μg doses of IIIB-rgp120/HIV-1 in alum adjuvant (10 vaccinees in each group), or alum adjuvant alone (8 vaccinees), at 0, 4, and 32 weeks by intramuscular injection. The three injections were well tolerated in both vaccine groups. Antibodies that neutralised homologous HIV-1IIIB were induced in 9 of 10 recipients after three 300 μg doses, and 6 of these 9 sera also neutralised heterologous HIV-1SF2. A dose response was evident, since three 100 μg injections induced lower titres of HIV-1IIIB neutralising antibodies and in fewer recipients (5 of 9) than the higher dose, with no neutralisation of HIV-1SF2. Similarly, syncytia-inhibiting, CD4-rgp120- blocking, and HIV-1IIIB V3-binding antibodies were induced in a dose dependent manner. Response to the 300 μg per dose vaccination occurred in a larger proportion of volunteers and at higher mean titres than seen in previous human trials with other recombinant envelope subunit vaccines or live vaccinia-env priming followed by envelope subunit boosting.
UR - http://www.scopus.com/inward/record.url?scp=0027178289&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0027178289&partnerID=8YFLogxK
U2 - 10.1016/0140-6736(93)91283-R
DO - 10.1016/0140-6736(93)91283-R
M3 - Article
C2 - 8100910
AN - SCOPUS:0027178289
SN - 0140-6736
VL - 342
SP - 69
EP - 73
JO - The Lancet
JF - The Lancet
IS - 8863
ER -